HAE Canada Patient Submissions

Patient Input for Lanadelumab (Takhzyro) to Institut National d’Excellence en Santé et en Services Sociaux (INESSS): Drug Evaluation Questionnaire for Patient and Caregiver Associations and Groups (December 2019)

Patient Input for CBS: HAEGARDA (C1 Esterase Inhibitor Subcutaneous – Human) for the prevention of swelling and/or painful attacks in adults and adolescents with HAE (December 2019)

Patient Input for CADTH CDR and pCODR Programs: Lanadelumab (Takhzyro) for the prevention of HAE in adolescents and adults (June 2019)

HAE Canada Input to the Common Drug Review at CADTH for Firazyr (lcatibant) (January 2014)